NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Clinical trial NCT04539808 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04539808
Sponsor: OHSU Knight Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Adenocarcinoma Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8 Stage I Pancreatic Cancer American Joint Committee on Cancer v8 Stage III Pancreatic Cancer American Joint Committee on Cancer v8 Stage IV Pancreatic Cancer American Joint Committee on Cancer v8

Start date: 2021-05-27
Primary completion: 2024-12-08
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.